A 68-year-old woman with a background of breast cancer (in remission for 5 years) and osteoporosis is on Alendronic acid 70 mg weekly and an aromatase...

Question

A 68-year-old woman with a background of breast cancer (in remission for 5 years) and osteoporosis is on Alendronic acid 70 mg weekly and an aromatase inhibitor (Letrozole). She asks whether the aromatase inhibitor affects her bone health. What is the correct advice?

Accepted Answer

Aromatase inhibitors accelerate bone loss by suppressing oestrogen production, increasing fracture risk - she should continue bone protection therapy and have regular DXA monitoring

Answer

Aromatase inhibitors have no effect on bone

Answer

Aromatase inhibitors strengthen bones

Answer

She should stop Alendronic acid as it interacts with Letrozole

Answer

Aromatase inhibitors only affect bone in men

uk-dgm MCQ (SBA): Aromatase Inhibitor-Induced Bone Loss

A 68-year-old woman with a background of breast cancer (in remission for 5 years) and osteoporosis is on Alendronic acid 70 mg weekly and an aromatase inhibitor (Letrozole). She asks whether the aromatase inhibitor affects her bone health. What is the correct advice?